Articles tagged "Malignancy"

2020 American Transplant Congress
Taking on Pediatric Liver Tumors – Beyond Hepatoblastoma
U. Ekong, N. Yazigi, K. Khan, S. Kaufman, J. Guerra, R. Girlanda, J. Hawksworth, A. Kroemer, C. Matsumoto, T. Fishbein
MedStar Georgetown Transplant Institute, Washington, DC
*Purpose: Background. Hepatic angiosarcomas, hepatocellular carcinoma, hemangioendothelioma, and rhabdomyosarcoma of the bile ducts are very rare tumors in children with historically poor prognosis. Median survival…
2020 American Transplant Congress
Treg Lymphotoxin Signals Promote Cancer Metastatic Migration: Mechanisms for Treg-Cancer Interaction
W. Piao¹, R. Oakes², C. Paluskievicz¹, Y. Xiong¹, L. Li¹, V. Saxena¹, M. WillsonShirkey¹, C. Jewell², J. Bromberg¹
¹Surgery, U of Maryland, Baltimore, MD, ²U of Maryland, College Park, MD
*Purpose: Immune suppressive therapy can be complicated by malignancy. Regulatory T cells (Treg) control immune tolerance for graft survival but cause to immune suppression in…
2020 American Transplant Congress
MTOR-Inhibitor Regimens and Malignancy after Kidney Transplantation: Can the Risk Be Modified by Considering Human Leukocyte Antigen (HLA) Mismatch in Immunosuppression Selection?
A. Santos¹, C. Chen¹, K. Alquadan², M. A. Leghrouz², X. Wen³
¹University of Florida, Gainesville, FL, ²Division of Nephrology, Hypertension, & Renal Transplantation, University of Florida, Gainesville, FL, ³Department of Pharmacy Practice, University of Rhode Island, Kingston, RI
*Purpose: We investigated the outcomes of mammalian target of rapamycin inhibitor (MTORI) regimens in adult kidney transplant (KT) recipients (KTRs) in categories of donor/recipient pre-transplant…
2020 American Transplant Congress
Is the Survival Impacted by Multiple Cancer after Liver Transplantation? A Retrospective French National Multicentric Study between 1993-2013
M. Altieri
Chu Caen, Caen, France
*Purpose: Introduction: Despite the great progress made in recent decades, post-liver transplant de novo cancers is one of the leading causes of late complications and…
2020 American Transplant Congress
Malignancy Incidence after Pediatric Kidney Transplantation; a Single-Center Experience in Japan
Y. Aoki¹, H. Satoh¹, R. Hamada², R. Harada², M. Muramatsu³, Y. Hamasaki³, S. Shishido³
¹Urology and Kidney Transplantation, Tokyo Metropolitan Children’s Medical Center, Tokyo, Japan, ²Nephrology, Tokyo Metropolitan Children’s Medical Center, Tokyo, Japan, ³Nephrology, Toho University, Faculty of Medicine, Tokyo, Japan
*Purpose: The incidence of malignancy was higher in organ transplant recipients than in the general population, and malignancies are a well-recognized complication of organ transplantation.…
2020 American Transplant Congress
Impact of Renal Transplant on the Outcomes of Breast Cancer Surgery
A. Choubey¹, A. Parsikia², D. Samson², M. Castaldi², R. Latifi², J. Ortiz¹
¹The University of Toledo, Toledo, OH, ²Westchester Medical Center, Valhalla, NY
*Purpose: Breast Carcinoma has the highest incidence of any cancer in adult females. The impact of a prior kidney transplant (KT) on breast cancer has…
2020 American Transplant Congress
Center Effects on Post-Transplant Outcomes in Liver Transplantation for Hilar Cholangiocarcinoma
S. Nagai¹, T. Kitajima¹, G. Sapisochin², D. Moonka¹, T. Hibi³
¹Henry Ford Hospital, Detroit, MI, ²University of Toronto, Toronto, ON, Canada, ³Kumamoto University, Kumamoto, Japan
*Purpose: Based on favorable outcomes reported by experienced centers, perihilar cholangiocarcinoma (Ph-CCA) has become an accepted indication for liver transplantation (LT). In the United States,…
2020 American Transplant Congress
Cancer Risk in Living Kidney Donors (LKDs) in the United States
E. Engels¹, K. Yu¹, S. Brown¹, K. Pawlish², C. Lynch³, B. Kasiske⁴, J. Snyder⁴, R. Pfeiffer¹
¹National Cancer Institute, Bethesda, MD, ²New Jersey Dept of Health, Trenton, NJ, ³Univ of Iowa, Iowa City, IA, ⁴Scientific Registry of Transplant Recipients, Minneapolis, MN
*Purpose: Individuals who wish to donate a kidney for transplantation are evaluated for transmissible diseases (including cancer) prior to donation. Outcomes in LKDs after donation…
2020 American Transplant Congress
Waiting List Mortality of Liver Tumors
V. G. Menon, Y. Chen, D. C. Chang, H. Yeh
Division of Transplantation, Massachusetts General Hospital, Boston, MA
*Purpose: Liver transplantation has been approved for hepatocellular carcinoma (HCC), hilar cholangiocarcinoma (CCA) and metastatic neuroendocrine tumors (NET), with the aim to produce similar outcomes…
2020 American Transplant Congress
Incidence of Skin Cancer – A Long Term Outcome of Immunosuppression in Renal Transplant Recipients Associated with the Usage of Azathioprine
H. Bheemreddy¹, S. Yusuf¹, N. Krishnan², A. Imtiaz³
¹Health and Life Sciences, Coventry University, Coventry, United Kingdom, ²Renal Unit, University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, ³Department of Dermatology, University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom
*Purpose: The main cause of mortality in Kidney Transplant Recipient’s (KTRs) is malignancy. The cancer incidence is increased by treating with immunosuppressive agents and longer…

« Previous Page
1
…
3
4
5
6
7
…
20
Next Page »